Early and midterm nonremission after transsphenoidal surgery in people with Cushing’s disease may be predicted by normalized early postoperative values for adrenocorticotropic hormone and cortisol, ...

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of ...

Please provide your email address to receive an email when new articles are posted on . A plasma adrenocorticotropic hormone suppression test performed shortly after surgical adenomectomy may ...

Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The ...

Cushing's syndrome is a complex endocrine disorder resulting from chronic hypercortisolism, which may arise from endogenous or exogenous sources. One of the most challenging diagnostic dilemmas in ...

Cushing's syndrome is a debilitating endocrine disorder which results from hypercortisolemia. While endogenous Cushing's syndrome can be caused by an adrenocorticotrophic hormone (ACTH)-dependent or ...

THE association of adrenal hyperplasia with basophil tumors of the pituitary gland was first suggested by Cushing. 1 This type of tumor has since been thought to be at least one cause of Cushing's ...

RnRMarketResearch.com adds "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2015" to its store. The report provides an overview of the Pituitary ACTH Hypersecretion (Cushing's ...

Visiongain has published a new report on Adrenocorticotropic Hormone (ACTH) Market Report 2021-2031: Forecasts By Type (ABQ-565, BIM-23B065, Corticotropin, Others, By Product (Natural, and Synthetic), ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease.